Full Text: COPYRIGHT 2001 American Medical
Association
Thousands of patients with failing hearts or other organs
die before a suitable donor organ for transplantation can
be located. Scientists have long suggessted that the worlwide
organ shortage could be alleviated by using animals such as
pigs as organ sources for human transplantations, if a major
obstacle - immunological incompatability - could be overcome.
Now researchers from two biotechnology companies - PPL Therapeutics
Plc (the Edinburg-based company that helped create Dolly,
the first cloned mammal) and Infigen, a DeForest, Wis-based
firm -- have taken a significant step toward overcoming that
obstacle with the creation of transgenic cloned piglets. Each
of the piglets has a marker gene (the PPL piglets have a jellyfish
gene that encodes a fluorescent protein and the Infigen piglets
have a neomvcim-resistance gene) to demonstrate the feasibility
of producing genetially idential animals from genetically
altered cells. |